Bavarian Nordic
195.70 DKK
+1.37 %
Less than 1K followers
BAVA
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+1.37 %
-0.91 %
+2.54 %
+2.54 %
-14.32 %
+30.64 %
-0.46 %
-31.67 %
+37.20 %
Bavarian Nordic is a biochemistry company. Today, the company specializes in the development, manufacture, and distribution of vaccines against infectious diseases in connection with cancer treatment. In addition, vaccines against other serious diseases such as Ebola and cervical cancer are also being developed. The largest operations are located in Europe and in the U.S. Bavarian Nordic was founded in 1994 and is headquartered in Kvistgaard, Denmark.
Read moreMarket cap
15.51B DKK
Turnover
46.5M DKK
Revenue
6.24B
EBIT %
28.89 %
P/E
11.12
Dividend yield-%
-
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
21/4
2026
General meeting '26
13/5
2026
Interim report Q1'26
21/8
2026
Interim report Q2'26
All
Research
Webcasts
Press releases
ShowingAll content types
Bavarian Nordic Submits Data to EMA to Extend Mpox and Smallpox Vaccine Approval to Children Aged 2-11 Years
Bavarian Nordic A/S – Notice Convening Annual General Meeting
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools